@article {FUKUMITSU2883, author = {NOBUYOSHI FUKUMITSU and HITOSHI ISHIKAWA and TAKESHI ARIMURA and HITOSHI WADA and TOMOAKI OKIMOTO and YOSHITAKA SATO and HIROMITSU IWATA and SHOSEI SHIMIZU and HIDEYUKI SAKURAI}, title = {Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan}, volume = {34}, number = {5}, pages = {2883--2889}, year = {2020}, doi = {10.21873/invivo.12116}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: This multi-institutional study aimed to investigate the efficacy and feasibility of proton beam therapy (PBT) for renal cell carcinoma (RCC) in Japan. Patients and Methods: The survival, local control, and toxicities in 22 RCC patients treated between 2001 and 2016 at 6 Japanese PBT institutes were analyzed. Results: The 22 patients comprised 20 men and had a median age of 67 (range=42-88) years. The total irradiation dose was 60-79.6 Gy (relative biological effectiveness). Over a median follow-up of 37 months, the 3-year overall and disease-specific survival rates were 95\% and 100\%, respectively, and no recurrence occurred. No patient experienced grade 3 or higher adverse events. The serum blood urea nitrogen (p=0.25) and creatinine levels (p=0.95) were not significantly affected, although the mean estimated glomerular filtration rate was reduced by 7.1{\textpm}11.2 ml/min/1.73 m2. Conclusion: Despite the small number of patients, high-dose PBT can control RCC while maintaining their renal function with high probability, and could be and alternative curative therapy especially for inoperable patients.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/34/5/2883}, eprint = {https://iv.iiarjournals.org/content/34/5/2883.full.pdf}, journal = {In Vivo} }